The objective of the filed IND Application is to start a Phase I/II study at multiple centers. The study would involve the use of retinal cells, which have been developed from the stem cells of the embryo for the treatment of patients suffering Stargardt’s Macular Dystrophy (SMD).
Neuralstem has raised a total of $5.228 M improving its financial position finalizing a $1.5 M private placement of 646,551 common shares at $2.32, priced at a 30% premium over the market on the closing, with an approximate $3.7 M from warrant exercises. CUR has also received notice from the NYSE Amex that the CUR is now in compliance with its listing requirements. These funds will help to support the further development of its stem cell technology and the ongoing Ph I ALS clinical trial.
The resulting effect of the reverse stock split is that every 8 shares of the issued/outstanding common stock prior to the opening of trading will be combined into 1 issued without any change in the par value of shares with the number of authorized but unissued shares of the common stock proportionally reduced. As a result, ASTM (D) could have approximately (rough calculation) 30 M shares outstanding with a total fully diluted value of 40 M including warrants and options.
Bioheart (BHRT.OB) is a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic, acute heart damage, and peripheral vascular disease. BHRT.OB initiated its REGEN trial, a Ph I clinical trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Read more…
STEM announced its proprietary HuCNS-SC® human neural stem cells have been used to treat the first patient enrolled in its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD), a myelination disorder that afflicts male children. Read more…
ReNeuron (LON: RENE) has been … finally … given full regulatory approval by the UK Gene Therapy Advisory Committee to initiate a stem cell trial for ischemic stroke after a 5 years approval cycle.
RENE.L also has new preclinical data backing the efficacy of its lead CTX stem cell line for peripheral arterial disease. Read more…
ASTM continues its cardiovascular clinical programs and expects to aggressively to advance these programs in 2010. Net loss was $4.575 M or $.03 per share. Read more…
BrainStorm Cell Therapeutics (BCLI.OB) is focused on developing adult stem cells taken from the patient’s own bone marrow to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease). BrainStorm’s technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes as demonstrated in animal models as it has successfully demonstrated release of dopamine from in-vitro differentiated bone marrow cells. Read more…
Aastrom has approved a 1 for 8 reverse stock split of the common stock effective on 2/18/10. The reverse stock split should help ASTM’ shares reflect the value created through their clinical programs and might help attract more institutional ownership of the stock. The reverse stock split is intended to increase the per share trading price of ASTM’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on NASDAQ. Following the reverse stock split, ASTM expects to have approximately 28.3 M shares of common stock outstanding. Read more…
ISCO.OB is focused on using hpSC to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven … clinically … yet is limited by the availability of safe immune-matched human cells. ISCO.OB is about to demonstrate the therapeutic applicability and potential immune rejection advantages of hpSC lines relative to other stem cell classes. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.